1. Scrip
  2. >>New Products

Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress

No Update On Plans For MDD Resubmission

 
• By Mandy Jackson

Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.

Wooden blocks with launching rocket graphic arranged in pyramid shape and a man is holding the top one.
Sage has finished building its commercial team for the December launch • Source: Shutterstock

The US Food and Drug Administration approval of Zurzuvae (zuranolone) in August did not go according to plan for Sage Therapeutics, Inc. and partner Biogen, Inc. While it was cleared to treat postpartum depression (PPD), the companies received a complete response letter (CRL) indicating an additional clinical trial would be needed to support approval in major depressive disorder (MDD), but the drug’s launch for new mothers with PPD is now progressing as expected following Drug Enforcement Administration scheduling.

Key Takeaways

  • Sage said Zurzuvae will launch for PPD in December now that the DEA has scheduled the drug.

  • The company and partner Biogen set a...

Sage said as part of its third quarter financial update on 7 November that Zurzuvae will officially reach the market in December now that the DEA has given the oral...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.